Skip to content

European Home Mechanical Ventilation Registry

European Home Mechanical Ventilation Registry

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02315339
Acronym
EHMVR
Enrollment
37
Registered
2014-12-11
Start date
2014-08-31
Completion date
2019-01-31
Last updated
2020-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis, Congenital Central Hypoventilation Syndrome, Duchenne Muscular Dystrophy, Kyphoscoliosis, Muscular Dystrophies, Myopathies, Myotonic Dystrophy, Obesity Hypoventilation Syndrome, Pulmonary Disease, Chronic Obstructive, Spinal Cord Injury

Brief summary

The European Home Mechanical Ventilation Registry (EHMVR) will enable a thorough evaluation of HMV by documenting the characteristics of HMV patients and their treatment. This will facilitate a prospective, observational study to identify the primary indications for HMV, describe patterns of HMV use in European countries, and characterize changes in the initiation and utilization of HMV over time. The registry will target all adult individuals who have an indication for HMV. In the EHMVR, patient data from routine clinical care will be documented using an electronic case report form (eCRF). The eCRF will record: patient demographic data; diagnostic information (including primary diagnosis, 6-minute walk time, the presence of depression, and quality of life); blood gases; ventilation treatment (including type of ventilator, modes and settings, interfaces used); follow-up data (including failure rates, side effects, technical issues). An initial Pilot Phase will be launched with the aim to enrol at least 200 patients over a 6-month period to determine the feasibility of the registry. Steering committee members and their institutions will be the main participants in the Pilot Phase. After completion of the Pilot Phase, the registry will be expanded across Europe with the goal of enrolling approximately 10,000 patients over 5 years.

Detailed description

The data (baseline and follow-up) should be collected as part of routine clinical care. In clinical practice, after HMV initiation, the first control examination (follow-up number one) with nocturnal diagnostics should take place within the first 4-8 weeks. Annual follow-up is required, and it is recommended that subsequent control visits should be performed 1-2 times a year. Each patient will be included for 5 years (total duration of the registry).

Interventions

None listed

Sponsors

Clinical Trial Center North Hamburg Germany
CollaboratorUNKNOWN
CRI-The Clinical Research Institute GmbH
CollaboratorINDUSTRY
ResMed
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients aged ≥18 years with an indication to receive HMV as part of routine clinical care * Patient is able to fully understand the study information and is willing to give informed consent * Patient, or the patient's legal guardian, signing the consent form

Exclusion criteria

\- No

Design outcomes

Primary

MeasureTime frame
Determine the mortality rate and the number of hospital readmissionsevery year (2014 to 2019), up to 5 years

Secondary

MeasureTime frame
Determine the effects of home mechanical ventilation on health-related quality of life using the EQ-5D and the Severe Respiratory Insufficiency questionnaires quality of lifeevery year (2014 to 2019), up to 5 years

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026